Table of Content

1 Report Overview
1.1 Pancreatic Endocrine Tumor Drug Definition
1.2 Market by Type
1.2.1 Global Pancreatic Endocrine Tumor Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Buparlisib Hydrochloride
1.2.3 Dovitinib Lactate
1.2.4 Fosbretabulin Tromethamine
1.2.5 Lanreotide Acetate
1.2.6 MPHE-001B
1.2.7 Others
1.3 Market Segment by Application
1.3.1 Global Pancreatic Endocrine Tumor Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Clinic
1.3.3 Research Center
1.3.4 Hospital
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Pancreatic Endocrine Tumor Drug Sales
2.1 Global Pancreatic Endocrine Tumor Drug Revenue Estimates and Forecasts 2018-2034
2.2 Global Pancreatic Endocrine Tumor Drug Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Pancreatic Endocrine Tumor Drug Revenue by Region
2.3.1 Global Pancreatic Endocrine Tumor Drug Revenue by Region (2018-2024)
2.3.2 Global Pancreatic Endocrine Tumor Drug Revenue by Region (2024-2034)
2.4 Global Pancreatic Endocrine Tumor Drug Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Pancreatic Endocrine Tumor Drug Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Pancreatic Endocrine Tumor Drug Sales Quantity by Region
2.6.1 Global Pancreatic Endocrine Tumor Drug Sales Quantity by Region (2018-2024)
2.6.2 Global Pancreatic Endocrine Tumor Drug Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Pancreatic Endocrine Tumor Drug Sales Quantity by Manufacturers
3.1.1 Global Pancreatic Endocrine Tumor Drug Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Pancreatic Endocrine Tumor Drug Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Pancreatic Endocrine Tumor Drug Sales in 2022
3.2 Global Pancreatic Endocrine Tumor Drug Revenue by Manufacturers
3.2.1 Global Pancreatic Endocrine Tumor Drug Revenue by Manufacturers (2018-2024)
3.2.2 Global Pancreatic Endocrine Tumor Drug Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Pancreatic Endocrine Tumor Drug Revenue in 2022
3.3 Global Pancreatic Endocrine Tumor Drug Sales Price by Manufacturers
3.4 Global Key Players of Pancreatic Endocrine Tumor Drug, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Pancreatic Endocrine Tumor Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Pancreatic Endocrine Tumor Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Pancreatic Endocrine Tumor Drug, Product Offered and Application
3.8 Global Key Manufacturers of Pancreatic Endocrine Tumor Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Pancreatic Endocrine Tumor Drug Sales Quantity by Type
4.1.1 Global Pancreatic Endocrine Tumor Drug Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Pancreatic Endocrine Tumor Drug Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Pancreatic Endocrine Tumor Drug Sales Quantity Market Share by Type (2018-2034)
4.2 Global Pancreatic Endocrine Tumor Drug Revenue by Type
4.2.1 Global Pancreatic Endocrine Tumor Drug Historical Revenue by Type (2018-2024)
4.2.2 Global Pancreatic Endocrine Tumor Drug Forecasted Revenue by Type (2024-2034)
4.2.3 Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Type (2018-2034)
4.3 Global Pancreatic Endocrine Tumor Drug Price by Type
4.3.1 Global Pancreatic Endocrine Tumor Drug Price by Type (2018-2024)
4.3.2 Global Pancreatic Endocrine Tumor Drug Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Pancreatic Endocrine Tumor Drug Sales Quantity by Application
5.1.1 Global Pancreatic Endocrine Tumor Drug Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Pancreatic Endocrine Tumor Drug Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Pancreatic Endocrine Tumor Drug Sales Quantity Market Share by Application (2018-2034)
5.2 Global Pancreatic Endocrine Tumor Drug Revenue by Application
5.2.1 Global Pancreatic Endocrine Tumor Drug Historical Revenue by Application (2018-2024)
5.2.2 Global Pancreatic Endocrine Tumor Drug Forecasted Revenue by Application (2024-2034)
5.2.3 Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Application (2018-2034)
5.3 Global Pancreatic Endocrine Tumor Drug Price by Application
5.3.1 Global Pancreatic Endocrine Tumor Drug Price by Application (2018-2024)
5.3.2 Global Pancreatic Endocrine Tumor Drug Price Forecast by Application (2024-2034)
6 North America
6.1 North America Pancreatic Endocrine Tumor Drug Sales by Company
6.1.1 North America Pancreatic Endocrine Tumor Drug Revenue by Company (2018-2024)
6.1.2 North America Pancreatic Endocrine Tumor Drug Sales Quantity by Company (2018-2024)
6.2 North America Pancreatic Endocrine Tumor Drug Market Size by Type
6.2.1 North America Pancreatic Endocrine Tumor Drug Sales Quantity by Type (2018-2034)
6.2.2 North America Pancreatic Endocrine Tumor Drug Revenue by Type (2018-2034)
6.3 North America Pancreatic Endocrine Tumor Drug Market Size by Application
6.3.1 North America Pancreatic Endocrine Tumor Drug Sales Quantity by Application (2018-2034)
6.3.2 North America Pancreatic Endocrine Tumor Drug Revenue by Application (2018-2034)
6.4 North America Pancreatic Endocrine Tumor Drug Market Size by Country
6.4.1 North America Pancreatic Endocrine Tumor Drug Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Pancreatic Endocrine Tumor Drug Revenue by Country (2018-2034)
6.4.3 North America Pancreatic Endocrine Tumor Drug Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Pancreatic Endocrine Tumor Drug Sales by Company
7.1.1 Europe Pancreatic Endocrine Tumor Drug Sales Quantity by Company (2018-2024)
7.1.2 Europe Pancreatic Endocrine Tumor Drug Revenue by Company (2018-2024)
7.2 Europe Pancreatic Endocrine Tumor Drug Market Size by Type
7.2.1 Europe Pancreatic Endocrine Tumor Drug Sales Quantity by Type (2018-2034)
7.2.2 Europe Pancreatic Endocrine Tumor Drug Revenue by Type (2018-2034)
7.3 Europe Pancreatic Endocrine Tumor Drug Market Size by Application
7.3.1 Europe Pancreatic Endocrine Tumor Drug Sales Quantity by Application (2018-2034)
7.3.2 Europe Pancreatic Endocrine Tumor Drug Revenue by Application (2018-2034)
7.4 Europe Pancreatic Endocrine Tumor Drug Market Size by Country
7.4.1 Europe Pancreatic Endocrine Tumor Drug Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Pancreatic Endocrine Tumor Drug Revenue by Country (2018-2034)
7.4.3 Europe Pancreatic Endocrine Tumor Drug Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Pancreatic Endocrine Tumor Drug Sales by Company
8.1.1 China Pancreatic Endocrine Tumor Drug Sales Quantity by Company (2018-2024)
8.1.2 China Pancreatic Endocrine Tumor Drug Revenue by Company (2018-2024)
8.2 China Pancreatic Endocrine Tumor Drug Market Size by Type
8.2.1 China Pancreatic Endocrine Tumor Drug Sales Quantity by Type (2018-2034)
8.2.2 China Pancreatic Endocrine Tumor Drug Revenue by Type (2018-2034)
8.3 China Pancreatic Endocrine Tumor Drug Market Size by Application
8.3.1 China Pancreatic Endocrine Tumor Drug Sales Quantity by Application (2018-2034)
8.3.2 China Pancreatic Endocrine Tumor Drug Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Pancreatic Endocrine Tumor Drug Sales by Company
9.1.1 APAC Pancreatic Endocrine Tumor Drug Sales Quantity by Company (2018-2024)
9.1.2 APAC Pancreatic Endocrine Tumor Drug Revenue by Company (2018-2024)
9.2 APAC Pancreatic Endocrine Tumor Drug Market Size by Type
9.2.1 APAC Pancreatic Endocrine Tumor Drug Sales Quantity by Type (2018-2034)
9.2.2 APAC Pancreatic Endocrine Tumor Drug Revenue by Type (2018-2034)
9.3 APAC Pancreatic Endocrine Tumor Drug Market Size by Application
9.3.1 APAC Pancreatic Endocrine Tumor Drug Sales Quantity by Application (2018-2034)
9.3.2 APAC Pancreatic Endocrine Tumor Drug Revenue by Application (2018-2034)
9.4 APAC Pancreatic Endocrine Tumor Drug Market Size by Region
9.4.1 APAC Pancreatic Endocrine Tumor Drug Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Pancreatic Endocrine Tumor Drug Revenue by Region (2018-2034)
9.4.3 APAC Pancreatic Endocrine Tumor Drug Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Pancreatic Endocrine Tumor Drug Sales by Company
10.1.1 Middle East, Africa and Latin America Pancreatic Endocrine Tumor Drug Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Pancreatic Endocrine Tumor Drug Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Pancreatic Endocrine Tumor Drug Market Size by Type
10.2.1 Middle East, Africa and Latin America Pancreatic Endocrine Tumor Drug Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Pancreatic Endocrine Tumor Drug Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Pancreatic Endocrine Tumor Drug Market Size by Application
10.3.1 Middle East, Africa and Latin America Pancreatic Endocrine Tumor Drug Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Pancreatic Endocrine Tumor Drug Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Pancreatic Endocrine Tumor Drug Market Size by Country
10.4.1 Middle East, Africa and Latin America Pancreatic Endocrine Tumor Drug Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Pancreatic Endocrine Tumor Drug Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Pancreatic Endocrine Tumor Drug Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Ipsen S.A.
11.1.1 Ipsen S.A. Company Information
11.1.2 Ipsen S.A. Overview
11.1.3 Ipsen S.A. Pancreatic Endocrine Tumor Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Ipsen S.A. Pancreatic Endocrine Tumor Drug Products and Services
11.1.5 Ipsen S.A. Pancreatic Endocrine Tumor Drug SWOT Analysis
11.1.6 Ipsen S.A. Recent Developments
11.2 Jiangsu Hengrui Medicine Co., Ltd.
11.2.1 Jiangsu Hengrui Medicine Co., Ltd. Company Information
11.2.2 Jiangsu Hengrui Medicine Co., Ltd. Overview
11.2.3 Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Products and Services
11.2.5 Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug SWOT Analysis
11.2.6 Jiangsu Hengrui Medicine Co., Ltd. Recent Developments
11.3 MediaPharma s.r.l.
11.3.1 MediaPharma s.r.l. Company Information
11.3.2 MediaPharma s.r.l. Overview
11.3.3 MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Products and Services
11.3.5 MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug SWOT Analysis
11.3.6 MediaPharma s.r.l. Recent Developments
11.4 Novartis AG
11.4.1 Novartis AG Company Information
11.4.2 Novartis AG Overview
11.4.3 Novartis AG Pancreatic Endocrine Tumor Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Novartis AG Pancreatic Endocrine Tumor Drug Products and Services
11.4.5 Novartis AG Pancreatic Endocrine Tumor Drug SWOT Analysis
11.4.6 Novartis AG Recent Developments
11.5 OXiGENE, Inc.
11.5.1 OXiGENE, Inc. Company Information
11.5.2 OXiGENE, Inc. Overview
11.5.3 OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Products and Services
11.5.5 OXiGENE, Inc. Pancreatic Endocrine Tumor Drug SWOT Analysis
11.5.6 OXiGENE, Inc. Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Pancreatic Endocrine Tumor Drug Value Chain Analysis
12.2 Pancreatic Endocrine Tumor Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Pancreatic Endocrine Tumor Drug Production Mode & Process
12.4 Pancreatic Endocrine Tumor Drug Sales and Marketing
12.4.1 Pancreatic Endocrine Tumor Drug Sales Channels
12.4.2 Pancreatic Endocrine Tumor Drug Distributors
12.5 Pancreatic Endocrine Tumor Drug Customers
13 Market Dynamics
13.1 Pancreatic Endocrine Tumor Drug Industry Trends
13.2 Pancreatic Endocrine Tumor Drug Market Drivers
13.3 Pancreatic Endocrine Tumor Drug Market Challenges
13.4 Pancreatic Endocrine Tumor Drug Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Pancreatic Endocrine Tumor Drug Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Buparlisib Hydrochloride
Table 3. Major Manufacturers of Dovitinib Lactate
Table 4. Major Manufacturers of Fosbretabulin Tromethamine
Table 5. Major Manufacturers of Lanreotide Acetate
Table 6. Major Manufacturers of MPHE-001B
Table 7. Major Manufacturers of Others
Table 8. Global Pancreatic Endocrine Tumor Drug Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 9. Global Pancreatic Endocrine Tumor Drug Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 10. Global Pancreatic Endocrine Tumor Drug Revenue by Region (2018-2024) & (US$ Million)
Table 11. Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Region (2018-2024)
Table 12. Global Pancreatic Endocrine Tumor Drug Revenue by Region (2024-2034) & (US$ Million)
Table 13. Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Region (2024-2034)
Table 14. Global Pancreatic Endocrine Tumor Drug Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Pcs)
Table 15. Global Pancreatic Endocrine Tumor Drug Sales by Region (2018-2024) & (K Pcs)
Table 16. Global Pancreatic Endocrine Tumor Drug Sales Market Share by Region (2018-2024)
Table 17. Global Pancreatic Endocrine Tumor Drug Sales by Region (2024-2034) & (K Pcs)
Table 18. Global Pancreatic Endocrine Tumor Drug Sales Market Share by Region (2024-2034)
Table 19. Global Pancreatic Endocrine Tumor Drug Sales Quantity by Manufacturers (2018-2024) & (K Pcs)
Table 20. Global Pancreatic Endocrine Tumor Drug Sales Quantity Share by Manufacturers (2018-2024)
Table 21. Global Pancreatic Endocrine Tumor Drug Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 22. Global Pancreatic Endocrine Tumor Drug Revenue Share by Manufacturers (2018-2024)
Table 23. Global Pancreatic Endocrine Tumor Drug Price by Manufacturers 2018-2024 (USD/Pcs)
Table 24. Global Key Players of Pancreatic Endocrine Tumor Drug, Industry Ranking, 2021 VS 2022
Table 25. Global Pancreatic Endocrine Tumor Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 26. Global Pancreatic Endocrine Tumor Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Pancreatic Endocrine Tumor Drug as of 2022)
Table 27. Global Key Manufacturers of Pancreatic Endocrine Tumor Drug, Manufacturing Base Distribution and Headquarters
Table 28. Global Key Manufacturers of Pancreatic Endocrine Tumor Drug, Product Offered and Application
Table 29. Global Key Manufacturers of Pancreatic Endocrine Tumor Drug, Date of Enter into This Industry
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Pancreatic Endocrine Tumor Drug Sales Quantity by Type (2018-2024) & (K Pcs)
Table 32. Global Pancreatic Endocrine Tumor Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 33. Global Pancreatic Endocrine Tumor Drug Sales Quantity Share by Type (2018-2024)
Table 34. Global Pancreatic Endocrine Tumor Drug Sales Quantity Share by Type (2024-2034)
Table 35. Global Pancreatic Endocrine Tumor Drug Revenue by Type (2018-2024) & (US$ Million)
Table 36. Global Pancreatic Endocrine Tumor Drug Revenue by Type (2024-2034) & (US$ Million)
Table 37. Global Pancreatic Endocrine Tumor Drug Revenue Share by Type (2018-2024)
Table 38. Global Pancreatic Endocrine Tumor Drug Revenue Share by Type (2024-2034)
Table 39. Pancreatic Endocrine Tumor Drug Price by Type (2018-2024) & (USD/Pcs)
Table 40. Global Pancreatic Endocrine Tumor Drug Price Forecast by Type (2024-2034) & (USD/Pcs)
Table 41. Global Pancreatic Endocrine Tumor Drug Sales Quantity by Application (2018-2024) & (K Pcs)
Table 42. Global Pancreatic Endocrine Tumor Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 43. Global Pancreatic Endocrine Tumor Drug Sales Quantity Share by Application (2018-2024)
Table 44. Global Pancreatic Endocrine Tumor Drug Sales Quantity Share by Application (2024-2034)
Table 45. Global Pancreatic Endocrine Tumor Drug Revenue by Application (2018-2024) & (US$ Million)
Table 46. Global Pancreatic Endocrine Tumor Drug Revenue by Application (2024-2034) & (US$ Million)
Table 47. Global Pancreatic Endocrine Tumor Drug Revenue Share by Application (2018-2024)
Table 48. Global Pancreatic Endocrine Tumor Drug Revenue Share by Application (2024-2034)
Table 49. Pancreatic Endocrine Tumor Drug Price by Application (2018-2024) & (USD/Pcs)
Table 50. Global Pancreatic Endocrine Tumor Drug Price Forecast by Application (2024-2034) & (USD/Pcs)
Table 51. North America Pancreatic Endocrine Tumor Drug Revenue by Company (2018-2024) & (US$ Million)
Table 52. North America Pancreatic Endocrine Tumor Drug Sales Quantity by Company (2018-2024) & (K Pcs)
Table 53. North America Pancreatic Endocrine Tumor Drug Sales Quantity by Type (2018-2024) & (K Pcs)
Table 54. North America Pancreatic Endocrine Tumor Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 55. North America Pancreatic Endocrine Tumor Drug Revenue by Type (2018-2024) & (US$ Million)
Table 56. North America Pancreatic Endocrine Tumor Drug Revenue by Type (2024-2034) & (US$ Million)
Table 57. North America Pancreatic Endocrine Tumor Drug Sales Quantity by Application (2018-2024) & (K Pcs)
Table 58. North America Pancreatic Endocrine Tumor Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 59. North America Pancreatic Endocrine Tumor Drug Revenue by Application (2018-2024) & (US$ Million)
Table 60. North America Pancreatic Endocrine Tumor Drug Revenue by Application (2024-2034) & (US$ Million)
Table 61. North America Pancreatic Endocrine Tumor Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 62. North America Pancreatic Endocrine Tumor Drug Revenue by Country (2018-2024) & (US$ Million)
Table 63. North America Pancreatic Endocrine Tumor Drug Revenue by Country (2024-2034) & (US$ Million)
Table 64. North America Pancreatic Endocrine Tumor Drug Sales Quantity by Country (2018-2024) & (K Pcs)
Table 65. North America Pancreatic Endocrine Tumor Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 66. Europe Pancreatic Endocrine Tumor Drug Sales Quantity by Company (2018-2024) & (K Pcs)
Table 67. Europe Pancreatic Endocrine Tumor Drug Revenue by Company (2018-2024) & (US$ Million)
Table 68. Europe Pancreatic Endocrine Tumor Drug Sales Quantity by Type (2018-2024) & (K Pcs)
Table 69. Europe Pancreatic Endocrine Tumor Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 70. Europe Pancreatic Endocrine Tumor Drug Revenue by Type (2018-2024) & (US$ Million)
Table 71. Europe Pancreatic Endocrine Tumor Drug Revenue by Type (2024-2034) & (US$ Million)
Table 72. Europe Pancreatic Endocrine Tumor Drug Sales Quantity by Application (2018-2024) & (K Pcs)
Table 73. Europe Pancreatic Endocrine Tumor Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 74. Europe Pancreatic Endocrine Tumor Drug Revenue by Application (2018-2024) & (US$ Million)
Table 75. Europe Pancreatic Endocrine Tumor Drug Revenue by Application (2024-2034) & (US$ Million)
Table 76. Europe Pancreatic Endocrine Tumor Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 77. Europe Pancreatic Endocrine Tumor Drug Revenue by Country (2018-2024) & (US$ Million)
Table 78. Europe Pancreatic Endocrine Tumor Drug Revenue by Country (2024-2034) & (US$ Million)
Table 79. Europe Pancreatic Endocrine Tumor Drug Sales Quantity by Country (2018-2024) & (K Pcs)
Table 80. Europe Pancreatic Endocrine Tumor Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 81. China Pancreatic Endocrine Tumor Drug Sales Quantity by Company (2018-2024) & (K Pcs)
Table 82. China Pancreatic Endocrine Tumor Drug Revenue by Company (2018-2024) & (US$ Million)
Table 83. China Pancreatic Endocrine Tumor Drug Sales Quantity by Type (2018-2024) & (K Pcs)
Table 84. China Pancreatic Endocrine Tumor Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 85. China Pancreatic Endocrine Tumor Drug Revenue by Type (2018-2024) & (US$ Million)
Table 86. China Pancreatic Endocrine Tumor Drug Revenue by Type (2024-2034) & (US$ Million)
Table 87. China Pancreatic Endocrine Tumor Drug Sales Quantity by Application (2018-2024) & (K Pcs)
Table 88. China Pancreatic Endocrine Tumor Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 89. China Pancreatic Endocrine Tumor Drug Revenue by Application (2018-2024) & (US$ Million)
Table 90. China Pancreatic Endocrine Tumor Drug Revenue by Application (2024-2034) & (US$ Million)
Table 91. APAC Pancreatic Endocrine Tumor Drug Sales Quantity by Company (2018-2024) & (K Pcs)
Table 92. APAC Pancreatic Endocrine Tumor Drug Revenue by Company (2018-2024) & (US$ Million)
Table 93. APAC Pancreatic Endocrine Tumor Drug Sales Quantity by Type (2018-2024) & (K Pcs)
Table 94. APAC Pancreatic Endocrine Tumor Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 95. APAC Pancreatic Endocrine Tumor Drug Revenue by Type (2018-2024) & (US$ Million)
Table 96. APAC Pancreatic Endocrine Tumor Drug Revenue by Type (2024-2034) & (US$ Million)
Table 97. APAC Pancreatic Endocrine Tumor Drug Sales Quantity by Application (2018-2024) & (K Pcs)
Table 98. APAC Pancreatic Endocrine Tumor Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 99. APAC Pancreatic Endocrine Tumor Drug Revenue by Application (2018-2024) & (US$ Million)
Table 100. APAC Pancreatic Endocrine Tumor Drug Revenue by Application (2024-2034) & (US$ Million)
Table 101. APAC Pancreatic Endocrine Tumor Drug Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 102. APAC Pancreatic Endocrine Tumor Drug Revenue by Region (2018-2024) & (US$ Million)
Table 103. APAC Pancreatic Endocrine Tumor Drug Revenue by Region (2024-2034) & (US$ Million)
Table 104. APAC Pancreatic Endocrine Tumor Drug Sales Quantity by Region (2018-2024) & (K Pcs)
Table 105. APAC Pancreatic Endocrine Tumor Drug Sales Quantity by Region (2024-2034) & (K Pcs)
Table 106. Middle East, Africa and Latin America Pancreatic Endocrine Tumor Drug Sales Quantity by Company (2018-2024) & (K Pcs)
Table 107. Middle East, Africa and Latin America Pancreatic Endocrine Tumor Drug Revenue by Company (2018-2024) & (US$ Million)
Table 108. Middle East, Africa and Latin America Pancreatic Endocrine Tumor Drug Sales Quantity by Type (2018-2024) & (K Pcs)
Table 109. Middle East, Africa and Latin America Pancreatic Endocrine Tumor Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 110. Middle East, Africa and Latin America Pancreatic Endocrine Tumor Drug Revenue by Type (2018-2024) & (US$ Million)
Table 111. Middle East, Africa and Latin America Pancreatic Endocrine Tumor Drug Revenue by Type (2024-2034) & (US$ Million)
Table 112. Middle East, Africa and Latin America Pancreatic Endocrine Tumor Drug Sales Quantity by Application (2018-2024) & (K Pcs)
Table 113. Middle East, Africa and Latin America Pancreatic Endocrine Tumor Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 114. Middle East, Africa and Latin America Pancreatic Endocrine Tumor Drug Revenue by Application (2018-2024) & (US$ Million)
Table 115. Middle East, Africa and Latin America Pancreatic Endocrine Tumor Drug Revenue by Application (2024-2034) & (US$ Million)
Table 116. Middle East, Africa and Latin America Pancreatic Endocrine Tumor Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 117. Middle East, Africa and Latin America Pancreatic Endocrine Tumor Drug Revenue by Country (2018-2024) & (US$ Million)
Table 118. Middle East, Africa and Latin America Pancreatic Endocrine Tumor Drug Revenue by Country (2024-2034) & (US$ Million)
Table 119. Middle East, Africa and Latin America Pancreatic Endocrine Tumor Drug Sales Quantity by Country (2018-2024) & (K Pcs)
Table 120. Middle East, Africa and Latin America Pancreatic Endocrine Tumor Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 121. Ipsen S.A. Company Information
Table 122. Ipsen S.A. Description and Overview
Table 123. Ipsen S.A. Pancreatic Endocrine Tumor Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 124. Ipsen S.A. Pancreatic Endocrine Tumor Drug Product and Services
Table 125. Ipsen S.A. Pancreatic Endocrine Tumor Drug SWOT Analysis
Table 126. Ipsen S.A. Recent Developments
Table 127. Jiangsu Hengrui Medicine Co., Ltd. Company Information
Table 128. Jiangsu Hengrui Medicine Co., Ltd. Description and Overview
Table 129. Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 130. Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Product and Services
Table 131. Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug SWOT Analysis
Table 132. Jiangsu Hengrui Medicine Co., Ltd. Recent Developments
Table 133. MediaPharma s.r.l. Company Information
Table 134. MediaPharma s.r.l. Description and Overview
Table 135. MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 136. MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Product and Services
Table 137. MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug SWOT Analysis
Table 138. MediaPharma s.r.l. Recent Developments
Table 139. Novartis AG Company Information
Table 140. Novartis AG Description and Overview
Table 141. Novartis AG Pancreatic Endocrine Tumor Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 142. Novartis AG Pancreatic Endocrine Tumor Drug Product and Services
Table 143. Novartis AG Pancreatic Endocrine Tumor Drug SWOT Analysis
Table 144. Novartis AG Recent Developments
Table 145. OXiGENE, Inc. Company Information
Table 146. OXiGENE, Inc. Description and Overview
Table 147. OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 148. OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Product and Services
Table 149. OXiGENE, Inc. Pancreatic Endocrine Tumor Drug SWOT Analysis
Table 150. OXiGENE, Inc. Recent Developments
Table 151. Key Raw Materials Lists
Table 152. Raw Materials Key Suppliers Lists
Table 153. Pancreatic Endocrine Tumor Drug Distributors List
Table 154. Pancreatic Endocrine Tumor Drug Customers List
Table 155. Pancreatic Endocrine Tumor Drug Market Trends
Table 156. Pancreatic Endocrine Tumor Drug Market Drivers
Table 157. Pancreatic Endocrine Tumor Drug Market Challenges
Table 158. Pancreatic Endocrine Tumor Drug Market Restraints
Table 159. Research Programs/Design for This Report
Table 160. Key Data Information from Secondary Sources
Table 161. Key Data Information from Primary Sources
List of Figures
Figure 1. Pancreatic Endocrine Tumor Drug Product Picture
Figure 2. Global Pancreatic Endocrine Tumor Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Pancreatic Endocrine Tumor Drug Market Share by Type in 2022 & 2034
Figure 4. Buparlisib Hydrochloride Product Picture
Figure 5. Dovitinib Lactate Product Picture
Figure 6. Fosbretabulin Tromethamine Product Picture
Figure 7. Lanreotide Acetate Product Picture
Figure 8. MPHE-001B Product Picture
Figure 9. Others Product Picture
Figure 10. Global Pancreatic Endocrine Tumor Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 11. Global Pancreatic Endocrine Tumor Drug Market Share by Application in 2022 & 2034
Figure 12. Clinic
Figure 13. Research Center
Figure 14. Hospital
Figure 15. Pancreatic Endocrine Tumor Drug Report Years Considered
Figure 16. Global Pancreatic Endocrine Tumor Drug Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 17. Global Pancreatic Endocrine Tumor Drug Revenue 2018-2034 (US$ Million)
Figure 18. Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 19. Global Pancreatic Endocrine Tumor Drug Sales Quantity 2018-2034 (K Pcs)
Figure 20. Global Pancreatic Endocrine Tumor Drug Sales Quantity Market Share by Region (2018-2024)
Figure 21. Global Pancreatic Endocrine Tumor Drug Sales Quantity Market Share by Region (2024-2034)
Figure 22. North America Pancreatic Endocrine Tumor Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 23. North America Pancreatic Endocrine Tumor Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 24. Europe Pancreatic Endocrine Tumor Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 25. Europe Pancreatic Endocrine Tumor Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 26. China Pancreatic Endocrine Tumor Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 27. China Pancreatic Endocrine Tumor Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 28. APAC Pancreatic Endocrine Tumor Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 29. APAC Pancreatic Endocrine Tumor Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 30. Middle East, Africa and Latin America Pancreatic Endocrine Tumor Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 31. Middle East, Africa and Latin America Pancreatic Endocrine Tumor Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 32. The Top 10 and Top 5 Players Market Share by Pancreatic Endocrine Tumor Drug Sales Quantity in 2022
Figure 33. The Top 10 and Top 5 Players Market Share by Pancreatic Endocrine Tumor Drug Revenue in 2022
Figure 34. Pancreatic Endocrine Tumor Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 35. Global Pancreatic Endocrine Tumor Drug Sales Quantity Market Share by Type (2018-2034)
Figure 36. Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Type (2018-2034)
Figure 37. Global Pancreatic Endocrine Tumor Drug Sales Quantity Market Share by Application (2018-2034)
Figure 38. Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Application (2018-2034)
Figure 39. North America Pancreatic Endocrine Tumor Drug Revenue Market Share by Company in 2022
Figure 40. North America Pancreatic Endocrine Tumor Drug Sales Quantity Market Share by Company in 2022
Figure 41. North America Pancreatic Endocrine Tumor Drug Sales Quantity Market Share by Type (2018-2034)
Figure 42. North America Pancreatic Endocrine Tumor Drug Revenue Market Share by Type (2018-2034)
Figure 43. North America Pancreatic Endocrine Tumor Drug Sales Quantity Market Share by Application (2018-2034)
Figure 44. North America Pancreatic Endocrine Tumor Drug Revenue Market Share by Application (2018-2034)
Figure 45. North America Pancreatic Endocrine Tumor Drug Revenue Share by Country (2018-2034)
Figure 46. North America Pancreatic Endocrine Tumor Drug Sales Quantity Share by Country (2018-2034)
Figure 47. U.S. Pancreatic Endocrine Tumor Drug Revenue (2018-2034) & (US$ Million)
Figure 48. Canada Pancreatic Endocrine Tumor Drug Revenue (2018-2034) & (US$ Million)
Figure 49. Europe Pancreatic Endocrine Tumor Drug Sales Quantity Market Share by Company in 2022
Figure 50. Europe Pancreatic Endocrine Tumor Drug Revenue Market Share by Company in 2022
Figure 51. Europe Pancreatic Endocrine Tumor Drug Sales Quantity Market Share by Type (2018-2034)
Figure 52. Europe Pancreatic Endocrine Tumor Drug Revenue Market Share by Type (2018-2034)
Figure 53. Europe Pancreatic Endocrine Tumor Drug Sales Quantity Market Share by Application (2018-2034)
Figure 54. Europe Pancreatic Endocrine Tumor Drug Revenue Market Share by Application (2018-2034)
Figure 55. Europe Pancreatic Endocrine Tumor Drug Revenue Share by Country (2018-2034)
Figure 56. Europe Pancreatic Endocrine Tumor Drug Sales Quantity Share by Country (2018-2034)
Figure 57. Germany Pancreatic Endocrine Tumor Drug Revenue (2018-2034) & (US$ Million)
Figure 58. France Pancreatic Endocrine Tumor Drug Revenue (2018-2034) & (US$ Million)
Figure 59. U.K. Pancreatic Endocrine Tumor Drug Revenue (2018-2034) & (US$ Million)
Figure 60. Italy Pancreatic Endocrine Tumor Drug Revenue (2018-2034) & (US$ Million)
Figure 61. Russia Pancreatic Endocrine Tumor Drug Revenue (2018-2034) & (US$ Million)
Figure 62. China Pancreatic Endocrine Tumor Drug Sales Quantity Market Share by Company in 2022
Figure 63. China Pancreatic Endocrine Tumor Drug Revenue Market Share by Company in 2022
Figure 64. China Pancreatic Endocrine Tumor Drug Sales Quantity Market Share by Type (2018-2034)
Figure 65. China Pancreatic Endocrine Tumor Drug Revenue Market Share by Type (2018-2034)
Figure 66. China Pancreatic Endocrine Tumor Drug Sales Quantity Market Share by Application (2018-2034)
Figure 67. China Pancreatic Endocrine Tumor Drug Revenue Market Share by Application (2018-2034)
Figure 68. APAC Pancreatic Endocrine Tumor Drug Sales Quantity Market Share by Company in 2022
Figure 69. APAC Pancreatic Endocrine Tumor Drug Revenue Market Share by Company in 2022
Figure 70. APAC Pancreatic Endocrine Tumor Drug Sales Quantity Market Share by Type (2018-2034)
Figure 71. APAC Pancreatic Endocrine Tumor Drug Revenue Market Share by Type (2018-2034)
Figure 72. APAC Pancreatic Endocrine Tumor Drug Sales Quantity Market Share by Application (2018-2034)
Figure 73. APAC Pancreatic Endocrine Tumor Drug Revenue Market Share by Application (2018-2034)
Figure 74. APAC Pancreatic Endocrine Tumor Drug Revenue Share by Region (2018-2034)
Figure 75. APAC Pancreatic Endocrine Tumor Drug Sales Quantity Share by Region (2018-2034)
Figure 76. Japan Pancreatic Endocrine Tumor Drug Revenue (2018-2034) & (US$ Million)
Figure 77. South Korea Pancreatic Endocrine Tumor Drug Revenue (2018-2034) & (US$ Million)
Figure 78. China Taiwan Pancreatic Endocrine Tumor Drug Revenue (2018-2034) & (US$ Million)
Figure 79. Southeast Asia Pancreatic Endocrine Tumor Drug Revenue (2018-2034) & (US$ Million)
Figure 80. India Pancreatic Endocrine Tumor Drug Revenue (2018-2034) & (US$ Million)
Figure 81. Middle East, Africa and Latin America Pancreatic Endocrine Tumor Drug Sales Quantity Market Share by Company in 2022
Figure 82. Middle East, Africa and Latin America Pancreatic Endocrine Tumor Drug Revenue Market Share by Company in 2022
Figure 83. Middle East, Africa and Latin America Pancreatic Endocrine Tumor Drug Sales Quantity Market Share by Type (2018-2034)
Figure 84. Middle East, Africa and Latin America Pancreatic Endocrine Tumor Drug Revenue Market Share by Type (2018-2034)
Figure 85. Middle East, Africa and Latin America Pancreatic Endocrine Tumor Drug Sales Quantity Market Share by Application (2018-2034)
Figure 86. Middle East, Africa and Latin America Pancreatic Endocrine Tumor Drug Revenue Market Share by Application (2018-2034)
Figure 87. Middle East, Africa and Latin America Pancreatic Endocrine Tumor Drug Sales Quantity Share by Country (2018-2034)
Figure 88. Middle East, Africa and Latin America Pancreatic Endocrine Tumor Drug Revenue Share by Country (2018-2034)
Figure 89. Brazil Pancreatic Endocrine Tumor Drug Revenue (2018-2034) & (US$ Million)
Figure 90. Mexico Pancreatic Endocrine Tumor Drug Revenue (2018-2034) & (US$ Million)
Figure 91. Turkey Pancreatic Endocrine Tumor Drug Revenue (2018-2034) & (US$ Million)
Figure 92. Israel Pancreatic Endocrine Tumor Drug Revenue (2018-2034) & (US$ Million)
Figure 93. GCC Countries Pancreatic Endocrine Tumor Drug Revenue (2018-2034) & (US$ Million)
Figure 94. Pancreatic Endocrine Tumor Drug Value Chain
Figure 95. Pancreatic Endocrine Tumor Drug Production Process
Figure 96. Channels of Distribution (Direct Vs Distribution)
Figure 97. Distributors Profiles
Figure 98. Bottom-up and Top-down Approaches for This Report
Figure 99. Data Triangulation
Figure 100. Key Executives Interviewed